A primary obstacle preventing community SCLC patients from joining clinical trials is not their unwillingness, but physicians not offering the option due to assumptions about patient interest or eligibility. The first step to improving enrollment is ensuring the conversation happens.
For acutely ill patients with strong clinical suspicion of SCLC, delaying treatment for biopsy confirmation can mean losing the window for effective intervention. Initiating chemotherapy in the hospital based on clinical presentation is a critical, potentially life-saving measure.
Integrating next-gen SCLC treatments like T-cell engagers requires more than education; it demands a physical and operational overhaul. Community practices must build infrastructure for 24-hour observation and establish proactive partnerships with specialists like ophthalmologists to manage novel toxicities.
As multiple new drugs like antibody-drug conjugates (ADCs) become available for SCLC, the critical research question will shift from *if* they work to *when* they should be used. Future biomarker strategies must focus on optimizing treatment sequences, considering factors like the drug's target and payload.
To make clinical trials more representative of real-world SCLC patients, who are often too sick to enroll, a pragmatic approach is emerging. Allowing one initial cycle of stabilizing chemotherapy before trial inclusion is a key strategy to broaden eligibility and gather more relevant data.